Clinical Trial

Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)

Study acronym: REASSURE
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to confirm or rule out the residual presence and viability of SARS- CoV-2 in the respiratory tract and lung parenchyma of patients previously infected with SARS-CoV-2. Presence and viability of SARS-CoV-2 in lung tissue will be assessed with reverse transcriptase-polymerase chain reaction (PCR) and viral culture. The histological location of residual SARS-CoV-2 will be determined with fluorescence immunohistochemistry and single molecule fluorescence in situ hybridization, targeting viral proteins and RNA respectively.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04775134
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions Covid19
Enrollment 75 participants
Start Date 2021-01-31
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-03